Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease
Background: The real-world EN-SEMBLE (jRCT1030220506) study investigated the effectiveness and safety of treatments subsequent to trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). This post hoc analysis provides i...
שמור ב:
| Principais autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2026-04-01
|
| סדרה: | Breast |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S0960977626000329 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
